CGON – Cg Oncology Inc
CG Oncology, Inc.CGON
$72.61Name : CG Oncology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,485,446,144.00
EPSttm : -2.76
CG Oncology, Inc.
$72.61
0.04%$0.03
CGON — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
15.02
Margin Of Safety %
Put/Call OI Ratio
0.37
EPS Next Q Diff
-0.11
EPS Last/This Y
-0.87
EPS This/Next Y
0.23
Price
72.67
Target Price
91.15
Analyst Recom
1.13
Performance Q
-5.65
Upside
-149.4%
Beta
0.29
Ticker: CGON
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | CGON | 63.15 | 0.21 | 0.61 | 39452 |
| 2026-10-13 | CGON | 62.45 | 0.23 | 0.51 | 41602 |
| 2026-10-14 | CGON | 61.83 | 0.23 | 1.46 | 42307 |
| 2026-10-15 | CGON | 61.86 | 0.23 | 1.00 | 42485 |
| 2026-10-16 | CGON | 59.88 | 0.23 | 0.53 | 43054 |
| 2026-10-19 | CGON | 60.02 | 0.20 | 0.09 | 34989 |
| 2026-10-20 | CGON | 61.91 | 0.21 | 0.49 | 36623 |
| 2026-10-21 | CGON | 62.22 | 0.22 | 0.48 | 38333 |
| 2026-10-22 | CGON | 62.51 | 0.23 | 4.56 | 38581 |
| 2026-10-23 | CGON | 61.66 | 0.26 | 2.94 | 39862 |
| 2026-10-26 | CGON | 61.61 | 0.27 | 3.83 | 40287 |
| 2026-10-27 | CGON | 62.96 | 0.28 | 0.22 | 40469 |
| 2026-10-28 | CGON | 63.98 | 0.28 | 0.60 | 40776 |
| 2026-10-29 | CGON | 63.42 | 0.28 | 9.38 | 41125 |
| 2026-10-30 | CGON | 64.7 | 0.30 | 0.15 | 41656 |
| 2026-11-02 | CGON | 62.05 | 0.28 | 0.54 | 43541 |
| 2026-11-03 | CGON | 64.08 | 0.28 | 4.12 | 43633 |
| 2026-11-04 | CGON | 67.78 | 0.36 | 0.80 | 47352 |
| 2026-11-05 | CGON | 64.78 | 0.36 | 0.11 | 59304 |
| 2026-11-06 | CGON | 75.93 | 0.35 | 0.38 | 60027 |
| 2026-11-09 | CGON | 74.87 | 0.37 | 1.20 | 70810 |
| 2026-11-10 | CGON | 72.68 | 0.37 | 2.18 | 70948 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | CGON | 63.13 | -42.0 | - | -3.23 |
| 2026-10-13 | CGON | 62.45 | -42.0 | - | -3.23 |
| 2026-10-14 | CGON | 61.90 | -42.0 | - | -3.23 |
| 2026-10-15 | CGON | 61.91 | -42.0 | - | -3.23 |
| 2026-10-16 | CGON | 59.87 | -42.0 | - | -3.23 |
| 2026-10-19 | CGON | 59.96 | -42.0 | - | -3.23 |
| 2026-10-20 | CGON | 59.96 | -42.0 | - | -3.23 |
| 2026-10-21 | CGON | 61.92 | -42.0 | - | -3.23 |
| 2026-10-22 | CGON | 62.56 | -42.0 | - | -3.23 |
| 2026-10-23 | CGON | 61.68 | -42.0 | - | -3.23 |
| 2026-10-26 | CGON | 61.56 | -42.0 | - | -3.23 |
| 2026-10-27 | CGON | 62.95 | -42.0 | - | -3.23 |
| 2026-10-28 | CGON | 63.99 | -42.0 | - | -3.23 |
| 2026-10-29 | CGON | 63.46 | -42.0 | - | -3.23 |
| 2026-10-30 | CGON | 64.61 | -42.0 | - | -3.23 |
| 2026-11-02 | CGON | 61.99 | -42.0 | - | -3.23 |
| 2026-11-03 | CGON | 64.07 | -42.0 | - | -3.23 |
| 2026-11-04 | CGON | 67.74 | -42.0 | - | -3.23 |
| 2026-11-05 | CGON | 64.80 | -42.0 | - | -3.23 |
| 2026-11-06 | CGON | 75.79 | -42.0 | - | -3.23 |
| 2026-11-09 | CGON | 74.79 | -64.3 | - | -3.23 |
| 2026-11-10 | CGON | 72.67 | -32.5 | - | -2.95 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-13 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-14 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-15 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-16 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-19 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-20 | CGON | 1.08 | 3.05 | 17.67 |
| 2026-10-21 | CGON | 1.13 | 3.05 | 17.67 |
| 2026-10-22 | CGON | 1.13 | 3.05 | 17.67 |
| 2026-10-23 | CGON | 1.13 | 3.05 | 17.67 |
| 2026-10-26 | CGON | 1.13 | 2.58 | 17.67 |
| 2026-10-27 | CGON | 1.13 | 2.58 | 15.02 |
| 2026-10-28 | CGON | 1.13 | 2.58 | 15.02 |
| 2026-10-29 | CGON | 1.13 | 2.58 | 15.02 |
| 2026-10-30 | CGON | 1.13 | 2.58 | 15.02 |
| 2026-11-02 | CGON | 1.13 | 2.59 | 15.02 |
| 2026-11-03 | CGON | 1.13 | 2.59 | 15.02 |
| 2026-11-05 | CGON | 1.13 | 2.59 | 15.02 |
| 2026-11-06 | CGON | 1.13 | 2.59 | 15.02 |
| 2026-11-09 | CGON | 1.13 | 3.43 | 15.02 |
| 2026-11-10 | CGON | 1.13 | 3.43 | 15.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.64
Avg. EPS Est. Current Quarter
-0.68
Avg. EPS Est. Next Quarter
-0.74
Insider Transactions
1.13
Institutional Transactions
3.43
Beta
0.29
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
27
Growth Score
54
Sentiment Score
89
Actual DrawDown %
10.3
Max Drawdown 5-Year %
Target Price
91.15
P/E
Forward P/E
PEG
P/S
1051.56
P/B
6.55
P/Free Cash Flow
EPS
-2.76
Average EPS Est. Cur. Y
-2.95
EPS Next Y. (Est.)
-2.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-3851.09
Relative Volume
0.87
Return on Equity vs Sector %
-50.3
Return on Equity vs Industry %
-30.5
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.28
EBIT Estimation
◆
CGON
Healthcare
$72.64
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
60.4
Range 1M
61.2%
Sup Dist
0.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-45.8%
EPS NY
-1.5%
52W%
80%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+25.5% upside
Upside
+25.5%
Quality
27
CGON — P/E HistoricalBiotechnology
CG Oncology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 142
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
CGON
Latest News
—
Caricamento notizie per CGON…
stock quote shares CGON – Cg Oncology Inc Stock Price stock today
news today CGON – Cg Oncology Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CGON – Cg Oncology Inc yahoo finance google finance
stock history CGON – Cg Oncology Inc invest stock market
stock prices CGON premarket after hours
ticker CGON fair value insiders trading